Abbott’s HUMIRA® (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn’s Disease

[at noodls] – Abbott Park, Illinois (NYSE: ABT) – Abbott announced today that the European Commission has approved HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn’s … more

View todays social media effects on ABT

View the latest stocks trending across Twitter. Click to view dashboard